Literature DB >> 15146183

Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.

Frank Rosenbauer1, Katharina Wagner, Jeffery L Kutok, Hiromi Iwasaki, Michelle M Le Beau, Yutaka Okuno, Koichi Akashi, Steven Fiering, Daniel G Tenen.   

Abstract

Transcription factors are believed to have a dominant role in acute myeloid leukemia (AML). This idea is supported by analysis of gene-knockout mice, which uncovered crucial roles of several transcription factors in normal hematopoiesis, and of individuals with leukemia, in whom transcription factors are frequently downregulated or mutated. However, analysis of knockout animals has not shown a direct link between abrogated transcription factors and the pathogenesis of AML. Sfpi1, encoding the lineage-specific transcription factor PU.1, is indispensable for normal myeloid and lymphoid development. We found that mice carrying hypomorphic Sfpi1 alleles that reduce PU.1 expression to 20% of normal levels, unlike mice carrying homo- or heterozygous deletions of Sfpi1, developed AML. Unlike complete or 50% loss, 80% loss of PU.1 induced a precancerous state characterized by accumulation of an abnormal precursor pool retaining responsiveness to G-CSF with disruption of M- and GM-CSF pathways. Malignant transformation was associated with a high frequency of clonal chromosomal changes. Retroviral restoration of PU.1 expression rescued myeloid differentiation of mutant progenitors and AML blasts. These results suggest that tightly graded reduction, rather than complete loss, of a lineage-indispensable transcription factor can induce AML.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15146183     DOI: 10.1038/ng1361

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  222 in total

1.  A microRNA expression signature of osteoclastogenesis.

Authors:  Toshifumi Sugatani; Jean Vacher; Keith A Hruska
Journal:  Blood       Date:  2011-01-27       Impact factor: 22.113

2.  RUNX1 regulates corepressor interactions of PU.1.

Authors:  Zhenbo Hu; Xiaorong Gu; Kristine Baraoidan; Vinzon Ibanez; Arun Sharma; ShriHari Kadkol; Reinhold Munker; Steven Ackerman; Giuseppina Nucifora; Yogen Saunthararajah
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

3.  Repression of Id2 expression by Gfi-1 is required for B-cell and myeloid development.

Authors:  Huajie Li; Ming Ji; Kimberly D Klarmann; Jonathan R Keller
Journal:  Blood       Date:  2010-05-07       Impact factor: 22.113

4.  RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1).

Authors:  R Katherine Hyde; P Paul Liu
Journal:  J Cell Biochem       Date:  2010-08-01       Impact factor: 4.429

Review 5.  Genome organizing function of SATB1 in tumor progression.

Authors:  Terumi Kohwi-Shigematsu; Krzysztof Poterlowicz; Ellen Ordinario; Hye-Jung Han; Vladimir A Botchkarev; Yoshinori Kohwi
Journal:  Semin Cancer Biol       Date:  2012-07-04       Impact factor: 15.707

6.  The Kruppel-like factor KLF4 is a critical regulator of monocyte differentiation.

Authors:  Mark W Feinberg; Akm Khyrul Wara; Zhuoxiao Cao; Maria A Lebedeva; Frank Rosenbauer; Hiromi Iwasaki; Hideyo Hirai; Jonathan P Katz; Richard L Haspel; Susan Gray; Koichi Akashi; Julie Segre; Klaus H Kaestner; Daniel G Tenen; Mukesh K Jain
Journal:  EMBO J       Date:  2007-08-30       Impact factor: 11.598

Review 7.  Dysregulation of the C/EBPalpha differentiation pathway in human cancer.

Authors:  Steffen Koschmieder; Balazs Halmos; Elena Levantini; Daniel G Tenen
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

8.  Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia.

Authors:  Iléana Antony-Debré; Vladimir T Manchev; Nathalie Balayn; Dominique Bluteau; Cécile Tomowiak; Céline Legrand; Thierry Langlois; Olivia Bawa; Lucie Tosca; Gérard Tachdjian; Bruno Leheup; Najet Debili; Isabelle Plo; Jason A Mills; Deborah L French; Mitchell J Weiss; Eric Solary; Remi Favier; William Vainchenker; Hana Raslova
Journal:  Blood       Date:  2014-12-09       Impact factor: 22.113

9.  miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.

Authors:  Jared A Wallace; Dominique A Kagele; Anna M Eiring; Carissa N Kim; Ruozhen Hu; Marah C Runtsch; Margaret Alexander; Thomas B Huffaker; Soh-Hyun Lee; Ami B Patel; Timothy L Mosbruger; Warren P Voth; Dinesh S Rao; Rodney R Miles; June L Round; Michael W Deininger; Ryan M O'Connell
Journal:  Blood       Date:  2017-04-21       Impact factor: 22.113

10.  Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors.

Authors:  Pia Riemke; Melinda Czeh; Josephine Fischer; Carolin Walter; Saeed Ghani; Matthias Zepper; Konstantin Agelopoulos; Stephanie Lettermann; Marie L Gebhardt; Nancy Mah; Andre Weilemann; Michael Grau; Verena Gröning; Torsten Haferlach; Dido Lenze; Ruud Delwel; Marco Prinz; Miguel A Andrade-Navarro; Georg Lenz; Martin Dugas; Carsten Müller-Tidow; Frank Rosenbauer
Journal:  EMBO J       Date:  2016-08-29       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.